TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04500366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socialization
Description: Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Socialization
Description: Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Group Exercise
Description: Participants will receive twice-weekly (one hour per class) virtual exercise via small-group physiotherapy sessions for a total of 12 weeks. All exercise sessions will occur virtually via a videoconferencing system. The classes will focus on functional movements specifically designed for seniors with frailty and mobility challenges, and will include modifications for gait aids such as canes or walkers. Class sizes will be small to allow for tailoring of exercises based on challenging, safe, progressive, evidence-based exercises. In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults, participants will also be provided with tailored supplemental home exercises developed by the study physiotherapist to gain an additional 1 hour of physical activity.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nutrition Consult and Protein Supplementation
Description: Nutrition Consult: Participants will be scheduled for a one-on-one virtual nutrition consult. During the consultation, study staff will assess the nutritional status of the participant and will provide them with counselling and coaching to improve their nutrition.~Protein Supplementation: Oral nutrition supplements commercially available from Nestle will be provided unless contraindicated. The oral nutrition supplement contains 360 calories and 14 grams of protein per serving. Participants are advised to take this with a meal or within 3 hours of exercise on activity days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Review
Description: A study pharmacist will review the participant's medication list and will utilize Beers and/or START/STOPP criteria to provide recommendations to optimize/update their medications to the participant's healthcare provider. Study geriatricians will be listed as contacts on the primary care provider recommendations and available for consultation.
Study: NCT00278577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Ablation and Hematopoietic Stem Cell Support
Description: Autologous Hematopoietic Stem Cell Transplant
Study: NCT03396796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus nerve-preserving group
Description: The modified vagus nerve-preserving procedure was performed in the following order: (1) left gastroepiploic vein along greater curvature; (2) the posterior surface of stomach, including the posterior gastric veins; (3) the left lateral surface of the distal esophagus; (4) the left inferior phrenic veins; (5) the posterior surface of the distal esophagus;(6) the anterior surface of the distal esophagus; and (7) the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved. the adherent junction between visceral peritoneum and the right crural diaphragm, and divided it into the lesser omental sac. The left gastric artery and vein and the posterior gastric veins were transected en bloc using a linear laparoscopic vascular stapler.
Study: NCT03817164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autonomic Nerve Modulation - Active
Description: Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Autonomic Nerve Modulation - Control
Description: Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
Study: NCT00005780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH-R
Description: EPOCH-R for 6 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) monthly with the vaccine for 5 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Idiotype vaccine
Description: 1 injection of vaccine monthly for 5 doses
Study: NCT03186300

Intervention type: DEVICE
Group type: OTHER
Intervention: PEPPER system
Description: In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
Study: NCT01938079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedative drug regimen
Description: (Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedative drug regimen
Description: (Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
Study: NCT00629980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite®
Description: ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Study: NCT02845323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab in combination with Urelumab
Description: Two cycles of Nivolumab Two cycles of Urelumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab monotherapy
Description: Two cycles of Nivolumab alone
Study: NCT03863886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound catheter (UM-2R/3R, Olympus)
Description: A miniprobe ultrasound catheter (UM-2R/3R, Olympus) will be passed into the colonoscope's accessory channel at the time of colonoscopy to measure the thickness of the different colon wall layers (mucosa, submucosa, muscular propria, and total wall thickness) in the cecum and rectum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound catheter (UM-2R/3R, Olympus)
Description: A miniprobe ultrasound catheter (UM-2R/3R, Olympus) will be passed into the colonoscope's accessory channel at the time of colonoscopy to measure the thickness of the different colon wall layers (mucosa, submucosa, muscular propria, and total wall thickness) in the cecum and rectum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound catheter (UM-2R/3R, Olympus)
Description: A miniprobe ultrasound catheter (UM-2R/3R, Olympus) will be passed into the colonoscope's accessory channel at the time of colonoscopy to measure the thickness of the different colon wall layers (mucosa, submucosa, muscular propria, and total wall thickness) in the cecum and rectum.
Study: NCT02997215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: lidocaine infusion during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: saline infusion at same rate as intervention group during surgery
Study: NCT03371836

Intervention type: DRUG
Group type: OTHER
Intervention: Clobazam
Description: Clobazam is used as an adjunct medicine for all participants.
Study: NCT02735863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: 50 mg or 150mg once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ABX464 matching placebo
Study: NCT01351103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGK974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGK974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Study: NCT03264586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-prilocaine cream
Description: 5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate penetration~- EMLA cream was applied, 1 hour before the expected time of birth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mepivacaine infiltration group
Description: 10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~* In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~* The suture procedure was delayed 10 minutes after the injection of the aneathetic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mediolateral episiotomy
Description: Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).~* At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound~* At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind~* The skin was closed with the same continuous suture to approximate the subcutinuous tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mediolateral episiotomy
Description: Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).~* At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound~* At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind~* The skin was closed with the same continuous suture to approximate the subcutinuous tissue.
Study: NCT02475590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Description: Laparoscopic Roux-en-Y gastric bypass
Study: NCT02560038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
Study: NCT02111421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 01
Description: Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,after the umbilical cord was clapped.The wight used to calculate the dose of dexmedetomidine would be that the total weight of the mother minus the weight of the placenta, amniotic fluid and fetal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmetomidine 02
Description: Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
Study: NCT02878499

Intervention type: OTHER
Group type: OTHER
Intervention: polysomnography
Study: NCT04467736

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gengigel Forte©
Description: Gengigel (hyaluronic acid) will be administered by the patient 3 times per day during 7 days following alveolar ridge preservation
Study: NCT03755206

Intervention type: OTHER
Group type: OTHER
Intervention: Sustainability strategies
Description: The investigators will work with each site to determine strategies that are relevant locally to help promote sustainability of the suicide prevention program.
Study: NCT03473756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Part A: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.
Study: NCT03538418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WAT
Description: The WAT intervention consists of 12 weekly WAT-based exercise sessions and 7 sessions of support for BCTs and technical issues.
Study: NCT00628017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids ( EPA+DHA)
Description: Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega-3 polyunsaturated fatty acids ( EPA+DHA)
Description: Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
Study: NCT04050553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01943344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVASURE CLOSURE DEVICE™
Description: implantation of VIVASURE CLOSURE DEVICE™
Study: NCT00635414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 15 minute intravenous infusion
Study: NCT01535040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine hydrochloride
Description: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo by mouth through completion of 12 weeks.
Study: NCT03919773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: This will be the matching placebo used in the study.
Study: NCT00558584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: protein A immunoadsorption
Description: protein-A immunoadsorption and i.v. IgG substitution

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: pseudo-immunoadsorption
Description: pseudo-immunoadsorption followed by an intravenous infusion without IgG
Study: NCT01832636

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alanyl-Glutamine
Description: Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alanyl-Glutamine
Description: Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alanyl-Glutamine
Description: Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanyl-Glutamine
Description: Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
Study: NCT00832663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: Effect of NSAID ingestion on muscle regeneration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: receive placebo
Study: NCT04675190

Intervention type: PROCEDURE
Intervention: Major abdominal Surgery
Description: Any surgery performed under general or regional anesthesia and procedures involving abdominal cavity is considered major abdominal surgery and those who have undergone any major abdominal surgery before 6 months from the date of ultrasound findings confirming the presence or absence of gall stone will be considered exposed.

Intervention type: PROCEDURE
Intervention: Major abdominal Surgery
Description: Any surgery performed under general or regional anesthesia and procedures involving abdominal cavity is considered major abdominal surgery and those who have undergone any major abdominal surgery before 6 months from the date of ultrasound findings confirming the presence or absence of gall stone will be considered exposed.
Study: NCT02632162

Intervention type: OTHER
Intervention: screening
Description: Screening for sleep disordered breathing with the ApnoeLink Air device

Intervention type: OTHER
Intervention: screening
Description: Screening for sleep disordered breathing with the ApnoeLink Air device
Study: NCT04004936

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQUIPPED with Active Feedback
Description: Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The active feedback group will receive one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQUIPPED with Passive Feedback
Description: Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The passive feedback group will receive monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
Study: NCT04368559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin for Injection
Description: Intravenous antifungal therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posaconazole
Description: Oral antifungal therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Oral antifungal therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMX)
Description: Oral antibacterial therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Microcrystalline cellulose
Study: NCT00619333

Intervention type: DRUG
Group type: OTHER
Intervention: follitropin and lutropin
Description: follitropin and lutropin
Study: NCT03207009

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LentiGlobin BB305 Drug Product
Description: LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Study: NCT04038060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-way SMS
Description: Participants will receive healthcare worker adherence support through 2-way SMS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-way SMS
Description: Participants will receive healthcare worker adherence support through 2-way SMS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug level feedback
Description: Participants will receive adherence counseling based on tenofovir drug levels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug level feedback
Description: Participants will receive adherence counseling based on tenofovir drug levels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly counseling sessions
Description: Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly counseling sessions
Description: Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence